SwedenBIO’s response: No to fee increases for clinical trials

There is a stated ambition to increase the number of clinical trials in Sweden, with several national initiatives. Att sharply increasing fees for clinical trials is not in line with these intentions. The government should therefore finance systemic and structural changes associated with the transition to EU regulation; and consider subsidizing the costs of processing applications to allow for competitive administrative processes at a reasonable cost. This contributes to making Sweden a attractive and competitive country for clinical trials from both Sweden and abroad.

Read SwedenBIO’s response to the Ministry of Social Affairs here.